Father, husband and associate professor/GI oncologist @ Wash U/SCC. Research interest #molecularprofiling #biomarker discovery #exosomes and #pharmacogenomics
St Louis, MO
Joined February 2014
- Tweets1.6K
- Following556
- Followers612
- Likes2.9K
Moh’d khushman retweeted
Would you like a glimpse of the future? Where solid tumor oncology may be heading?
Look no further.
Agenus may have had some ups and downs in the past (BATMAN -> ROBBIN), but Bot Bal looks like it has the capacity to absolutely change how we manage MSS solid tumors.
UNICORN, now in Nature Medicine. Phase 2, non-randomized, window-of-opportunity. Resectable rT3-4 colon cancer. One dose of botensilimab, two doses of balstilimab, surgery around day 30-40.
Highlights:
MPR 36% (5/14) in MSS disease, pCR 29%. Omg. (compare to FOLFOX in FOxTROT: 8%)
Bot alone in MSS: 0%. The PD-1 matters.
dMMR Bot Bal: MPR 100%, pCR 93%
😍12-month EFS 100% in both Bot Bal cohorts
Yes there is tox. irAEs in 54%, mostly flu-like symptoms, and only one grade 3 (hyperthyroidism). No grade 3 diarrhea.
Every MSS responder cleared ctDNA before surgery, that’s a helpful tool for predicting response in a disease that may fibrose and stay visible on imaging.
The holy grail is almost here: melting the majority of rectal cancers away. In MSI-H we have AZUR-1. In MSS, perhaps we have this in the future.
nature.com/articles/s41591-0…
@OncoAlert @TheGutOncLab @Onco_Nexus
Moh’d khushman retweeted
🧬 What could a PD-1/TGF-β bispecific add to an established mCRC regimen?
WATCH: @khushmanmd, of @SitemanCenter, discusses the rationale and design of the phase 3 INCA033890-303 trial. #crcsm #medtwitter #oncology
onclive.com/view/dr-khushman…
Moh’d khushman retweeted
Today, an @FDA advisory panel voted 7–2, with 1 abstention, that the benefits of @GrailBio Galleri multi-cancer early detection (MCED) test outweigh its risks. A closely watched milestone for the field.
And if you haven’t seen it yet, the NHS-Galleri randomized trial was published yesterday in @NEJM:
nejm.org/doi/abs/10.1056/NEJ…
Moh’d khushman retweeted
The GRAIL NHS Galleri randomized trial with over 142,000 participants was published today @NEJM
"In this trial, we did not observe a lower incidence rate of stage III or IV cancers [the primary endpoint] across 12 prespecified cancers after three screening rounds with multicancer early-detection testing plus usual care than with usual care alone."
nejm.org/doi/full/10.1056/NE…
Moh’d khushman retweeted
"Rasonque will cost $39,800 for a month’s supply of pills, before customary insurance discounts and rebates, the company said."
$39,800 * 12 = $477,600 per year...
Before rebates and discounts, which may bring the price down for some insurers. Note that is not an out-of-pocket cost -- patients will not pay that.
statnews.com/2026/08/26/panc…
Moh’d khushman retweeted
Important caveat:
The @FDA Daraxonrasib (Rasonque) approval is REALLY broad & the "OR" in the indication below potentially opens the door for a "soft 1st line" extension. Also, no requirement to document KRAS status, acknowledging that 95% of #PancreaticCancer harbor a mutation.
Moh’d khushman retweeted
🔥🔥🔥
DARAXONRASIB APPROVED FOR METASTATIC #PancreaticCancer
fda.gov/news-events/press-an…
Moh’d khushman retweeted
Amazing news today, culmination of years of research & clinical trials in #PancreaticCancer.
The @RevMedicines approval for Rasonque (Daraxonrasib) will open many doors, including other inhibitors in this space & combinations. @OncoAlert @KRASKickers
fda.gov/news-events/press-an…
In April, Newsweek named @SitemanCenter among America’s Best Hospitals for cancer care, noting breast, colorectal, lung and prostate cancer as standout specialties.
rankings.newsweek.com/americ…
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer prnewswire.com/news-releases…
Moh’d khushman retweeted
One week to go - #ASCO26 abstracts dropped today!
@ASCO #Chicago #GIcancers
➡️asco.org/annual-meeting/prog…
#ASCO26 is <4 weeks away! @ASCO
Here are the #GI oncology oral abstracts I’m most excited about 👇
➡️Notable phase 3s:
PDAC: RASolute302 ⭐️
HCC: EMERALD-3 & IMBRAVE251
EGC: ATTRACTION 6 & BL-B01D1-305
CC: FIGHT-302
CRC: PUMP (HAI), EPISODE-III (ASA)
- HER2+: Tras rezetecan (SHR-A1811)
- BRAFm: Tunlametinib in pre-treated
Congrats to all the presenters - special shoutout to our 🇨🇦 GI oral presenters & discussants 🤗
See you in Chicago!
#GIOncology #CRC #PDAC #RAS #HCC
ORR: 24.2% (2 CR & 14 PR).PFS was 6.4m CRC & 3.5 m melanoma. Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600–Mutant Solid Tumors | Journal of Clinical Oncology ascopubs.org/doi/abs/10.1200…
Moh’d khushman retweeted
1/n
Daraxonrasib (RMC-6236), the first-in-human oral 💊RAS(ON) multi-selective tri-complex inhibitor, in previously treated RAS-mutated pancreatic cancer phase I/II study is now published in the New England Journal of Medicine @NEJM
A novel💡 way to shut down ⚔️RAS, one of the most important oncogenic drivers in cancer that had long been considered “undruggable.”
🔗nejm.org/doi/full/10.1056/NE…
Shout out to Brian Wolpin, @CentralParkWMD @GarridoLagunaMD @AlexSpiraMDPhD @salmanpunekar @MeredithPelster @bherzbergmd Nilo Azad Aparna Hegde @DavidHongMD and the whole team who dedicated to this study. @EileenMOReilly
#HBP #HumansBeyondPatients – at Manhattan, NY
Moh’d khushman retweeted
#ASCO26 is <4 weeks away! @ASCO
Here are the #GI oncology oral abstracts I’m most excited about 👇
➡️Notable phase 3s:
PDAC: RASolute302 ⭐️
HCC: EMERALD-3 & IMBRAVE251
EGC: ATTRACTION 6 & BL-B01D1-305
CC: FIGHT-302
CRC: PUMP (HAI), EPISODE-III (ASA)
- HER2+: Tras rezetecan (SHR-A1811)
- BRAFm: Tunlametinib in pre-treated
Congrats to all the presenters - special shoutout to our 🇨🇦 GI oral presenters & discussants 🤗
See you in Chicago!
#GIOncology #CRC #PDAC #RAS #HCC
Moh’d khushman retweeted
Revolution Medicines Statement on FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer
ir.revmed.com/news-releases/…
Duloxetine Not Effective in Preventing Oxaliplatin-Induced Peripheral Neuropathy. 👉Adherence rates were below 75% in all study arms. 👉 No statistically or clinically meaningful difference between the treatment arms. ascopost.com/news/april-2026…
Moh’d khushman retweeted
#ASCO26 is coming up!
With abstracts released I put together a top 10 (ok, top 12) GI abstracts I'm excited for.
Some things might fall off (or be added) pending full abstract text, but these are what I'm watching for and might be practice changing or scientifically interesting.
@ASCO @Onco_Nexus @OncoAlert @TheGutOncLab
Moh’d khushman retweeted
🚨 Mosperafenib enters the BRAF arena! A next-gen paradox breaker for BRAF V600 tumors: ascopubs.org/doi/abs/10.1200… @JCO_ASCO
▪️ Phase I (n=80; 60% prior BRAFi; 63 CRC, 13 melanoma)
▪️ MTD not reached → favorable safety
▪️ G3–4 TRAEs: 16.3%; no G5
▪️ ORR: 24.2% (2 CRs, 14 PRs)
▪️ Sustained target inhibition (pERK ≥90%)
▪️ mPFS: 6.4 mo (CRC) | 3.5 mo (melanoma)
Breaking the paradox…one BRAF at a time 🧩
@OncoAlert @OncoReporte @myESMO @_SEOM @GrupoTTD @GrupoMelanoma @MelanomaReAlli @SocietyMelanoma
